Evoke Net Income from 2010 to 2026
| EVOK Stock | USD 30.15 0.85 2.74% |
Net Loss | First Reported 2011-12-31 | Previous Quarter -1.6 M | Current Value -1.2 M | Quarterly Volatility 1.3 M |
Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 M, Interest Expense of 605.4 K or Selling General Administrative of 18.2 M, as well as many indicators such as Price To Sales Ratio of 0.9, Dividend Yield of 0.0 or PTB Ratio of 2.74. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
Evoke | Net Income | Build AI portfolio with Evoke Stock |
Historical Net Income data for Evoke Pharma serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Evoke Pharma represents a compelling investment opportunity.
Latest Evoke Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Evoke Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Evoke Pharma financial statement analysis. It represents the amount of money remaining after all of Evoke Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Evoke Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evoke Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.35 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Evoke Net Income Regression Statistics
| Arithmetic Mean | (7,388,391) | |
| Coefficient Of Variation | (52.69) | |
| Mean Deviation | 3,191,388 | |
| Median | (7,566,080) | |
| Standard Deviation | 3,893,177 | |
| Sample Variance | 15.2T | |
| Range | 11.2M | |
| R-Value | (0.16) | |
| Mean Square Error | 15.7T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | (126,923) | |
| Total Sum of Squares | 242.5T |
Evoke Net Income History
Other Fundumenentals of Evoke Pharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
About Evoke Pharma Financial Statements
Evoke Pharma investors utilize fundamental indicators, such as Net Income, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Evoke Pharma Correlation against competitors. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.38) | Revenue Per Share | Quarterly Revenue Growth 0.614 | Return On Assets | Return On Equity |
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.